Japan now part of global dapagliflozin alliance
This article was originally published in Scrip
Executive Summary
AstraZenecaand Bristol-Myers Squibbhave extended their global alliance for the development and commercialisation of dapagliflozin to Japan, the only country excluded from the original agreement.